Today's Research Report Coverage on Medical Supplies Stocks -- Antares Pharma, Integra LifeSciences, Becton, Dickinson, and Waters

Tuesday, July 25, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 25, 2017 /PRNewswire/ --

If you want a Stock Review on ATRS, IART, BDX, or WAT then come over to

and sign up for your free customized report today. While the Medical Instrument and Supply Manufacturing space has many large operators, small and medium businesses have traditionally dominated the market. IBISWorld estimates that, in 2017, the industry's
four largest players will hold a combined market share of 21.4% of the total industry revenue, which indicates a low level of industry concentration. Pre-market today, brings focus on these four companies: Antares Pharma Inc. (NASDAQ: ATRS), Integra LifeSciences Holdings Corp. (NASDAQ: IART), Becton, Dickinson and Co. (NYSE: BDX), and Waters Corp. (NYSE: WAT). Learn more about these stocks by signing up for their free reports on at:

Antares Pharma 

On Monday, shares in Ewing, New Jersey headquartered Antares Pharma Inc. recorded a trading volume of 691,434 shares. The stock ended the session 3.64% higher at $3.13. The Company's shares have gained 3.99% in the last one month, 11.39% over the previous three months, and 34.33% on an YTD basis. The stock is trading 8.33% above its 50-day moving average and 28.05% above its 200-day moving average. Moreover, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have a Relative Strength Index (RSI) of 52.93. The free research report on ATRS is available at:

Integra LifeSciences 

Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp.'s stock closed the day 0.27% higher at $55.19. A total volume of 650,092 shares was traded, which was above their three months average volume of 532,420 shares. The Company's shares have advanced 2.56% in the past month, 28.71% in the previous three months, and 28.66% since the start of this year. The stock is trading 6.27% and 24.05% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Integra LifeSciences, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, have an RSI of 62.16.

On June 30th, 2017, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $65 per share.

On July 11th, 2017, Integra LifeSciences announced that it will release its Q2 2017 financial results on July 26th, 2017. In conjunction with the earnings release, the Company will host a conference call at 8:30 a.m. ET on the same day to discuss the results. Peter J. Arduini, President and CEO, and Glenn G. Coleman, CFO and Corporate Vice-President of International, will review Q2 2017 results during the call. The complimentary report on IART can be downloaded at:

Becton, Dickinson 

Shares in Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co. recorded a trading volume of 1.63 million shares. The stock ended yesterday's trading session 0.16% higher at $205.63. The Company's shares have advanced 5.42% in the past month, 16.13% in the previous three months, and 24.21% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.74% and 14.17%, respectively. Furthermore, shares of Becton, Dickinson and Co., which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have an RSI of 77.31.

On June 30th, 2017, research firm Raymond James upgraded the Company's stock rating from 'Outperform' to 'Strong Buy'

On July 18th, 2017, Becton, Dickinson and Co. announced a new technology that can automatically report and release negative urine cultures. The BD Kiestra™ urine culture app, together with BD BBL™ plated media, uses digital imaging and software algorithms to determine the amount of growth on a urine culture plate from clean caught and catheterized samples. Visit us today and download our complete research report on BDX for free at:


Milford, Massachusetts-based Waters Corp.'s stock finished Monday's session 0.12% lower at $185.01. A total volume of 734,048 shares was traded, which was above their three months average volume of 492,260 shares. The Company's shares have advanced 0.06% in the last one month, 15.44% over the previous three months, and 37.67% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.82% and 17.67%, respectively. Additionally, shares of Waters, which operates as an analytical instrument manufacturer in the US and internationally, have an RSI of 56.90.

On July 05th, 2017, Waters announced that it will webcast its Q2 2017 financial results conference call live on July 25th, 2017, at 8:00 a.m. ET. The conference call may be accessed under the "Investors" section of the Company's website. Get free access to your technical report on WAT at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store